Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation
Jenifer Masip(Hospital Universitari Joan XXIII de Tarragona), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud), Yolanda M. Pacheco(Instituto de Biomedicina de Sevilla), Rosa Jorba(Institut de Recerca Biomèdica Catalunya Sud), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Fréderic Gómez-Bertomeu, Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Estebán Martínez(Instituto de Salud Carlos III), Miguel López-Dupla, Sergi Veloso, Montserrat Olona(Institut de Recerca Biomèdica Catalunya Sud), Graciano García‐Pardo(Instituto de Salud Carlos III), Joaquim Peraire(Instituto de Salud Carlos III), Verònica Alba
Cited by 4
Related Papers
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
|New England Journal of Medicine|2023|476
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143